Effect of Recombinant Human Brain Natriuretic Peptide and Sacubitril Valsartan in NSTEMI Patients with Acute Heart Failure
Objective:To study the value of Recombinant Human Brain Natriuretic Peptide and Sacubitril Valsartan in non-ST segment elevation myocardial infarction(NSTEMI)patients with acute heart failure.Method:A total of 70 hospitalized patients diagnosed with NSTEMI and acute heart failure treated from August 2020 to March 2022 in Heyuan People's Hospital were selected,they were divided into a study group and a control group by random number table method,with 35 cases in each group.The study group received treatment with Recombinant Human Brain Natriuretic Peptide and Sacubitril Valsartan,while the control group received treatment with Recombinant Human Brain Natriuretic Peptide and Valsartan.The total effective rate,heart rate,blood pressure,urine volume,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),N-terminal pro-B-type natriuretic peptide(NT-proBNP)and major adverse cardiovascular events(MACE)between the two groups were compared.Result:The total effective treatment rate in the study group(88.57%)was higher than that in the control group(68.57%),the difference was statistically significant(P＜0.05).Before medication,there were no statistically significant differences in heart rate,blood pressure,urine output,creatinine,and blood potassium between the two groups(P＞0.05);72 hours and 7 days after medication,the heart rate,systolic blood pressure,diastolic blood pressure,and creatinine in the study group were lower than those in the control group,while urine output was higher than that in the control group,the differences were statistically significant(P＜0.05);there were no statistically significant differences in blood potassium between the two groups(P＞0.05).Before medication,there were no statistically significant differences in heart function and NT-proBNP between the two groups(P＞0.05).After 3 and 6 months of medication,the LVEF of the study group was higher than that of the control group,but LVEDD,LVESD,and NT-proBNP were all lower than those of the control group,the differences were statistically significant(P＜0.05).The incidence of adverse cardiac events in the study group was lower than that in the control group(P＜0.05).Conclusion:The Recombinant Human Brain Natriuretic Peptide and Sacubitril Valsartan can effectively control the blood pressure and heart rate,improve the cardiac function and reduce the incidences of adverse cardiovascular events.
国家科技期刊平台
NSTL
万方数据
维普
